
Effect of Vinpocetine on Cerebral Blood Flow in Patients with Cerebrovascular Disorders
Norihiko Tamaki M.D., Tadaki Kusunoki M.D., Satoshi Matsumoto M.D.
Department of Neurosurgery.
Kobe University School of Medicine.
Kobe, Japan
Advances in therapy 1985; 2:53-6
Abstract
The 133xenon inhalation method was used in an open-label clinical trial to examine changes in cerebral blood flow (CBF) after
vinpocetine treatment in 13 patients with cerebrovascular disorders. In all patients, measurement of regional cerebral blood flow (RCBF) was made prior to and after treatment with
vinpocetine 5 mg t.i.d. for five to seven weeks. In ten of the patients, treatment was continued for a total of 8 to 16 weeks with an additional RCBF measurement at the end of their treatment.
The results showed a significant increase in the Initial Slope Index (ISI) values of mean total CBF, and RCBF for the involved hemisphere after six weeks of treatment with
vinpocetine.
The CBF for the involved lobe was significantly increased for ISI and flow rate of gray matter at six weeks and at the end of treatment.
No adverse reactions were reported.